Sandbox Captopril tablet
For information about Captopril, click here.

# Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider.  WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery.  The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements.  WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

# Overview
Sandbox Captopril tablet is {{{aOrAn}}} {{{drugClass}}} drug that is FDA approved for the treatment of {{{indication}}}.   Adverse reactions include {{{adverseReactions}}}.

## Off-Label Use and Dosage (Adult)

### Guideline-Supported Use

### Acute ST segment elevation myocardial infarction=
- Developed by: American College of Cardiology Foundation(ACCF) and American Heart Association (AHA)
- Class of Recommendation: Class I
- Level of Evidence: Level A
- Dosing Information
- An angiotensin-converting enzyme (ACE) inhibitor should be administered within the first 24 hours to all patients with STEMI with anterior location, HF, or ejection fraction (EF) less than or equal to 0.40, unless contraindicated.

### NonGuideline-Supported Use
- Dosing Information
- (Dosage)
- Dosing Information
- (Dosage)
- Dosing Information
- (Dosage)==Pediatric Indications and Dosage==

## FDA-Labeled Indications and Dosage (Pediatric)
- Dosing Information
- (Dosage)
- Dosing Information
- (Dosage)===Off-Label Use and Dosage (Pediatric)===

### Guideline-Supported Use
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)====NonGuideline-Supported Use====
- Dosing Information
- (Dosage)
- Dosing Information
- (Dosage)
- Dosing Information
- (Dosage)

# Contraindications
- Hypersensitivity to this product or any other angiotensin-converting enzyme inhibitor
- History of angioedema during therapy with any other ACE inhibitor)

# Warnings
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue captopril as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mothers and fetus.
In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue, captopril unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to captopril for hypotension, oliguria, and hyperkalemia.
When captopril was given to rabbits at doses about 0.8 to 70 times (on a mg/kg basis) the maximum recommended human dose, low incidences of craniofacial malformations were seen. No teratogenic effects of captopril were seen in studies of pregnant rats and hamsters. On a mg/kg basis, the doses used were up to 150 times (in hamsters) and 625 times (in rats) the maximum recommended human dose.

# Adverse Reactions

## Clinical Trials Experience

## Postmarketing Experience
(Description)

# Drug Interactions
- Drug 1
- Drug 2
- Drug 3
- Drug 4
- Drug 5
(Description)
(Description)
(Description)
(Description)
(Description)

# Use in Specific Populations

### Pregnancy
(Description)
(Description)

### Labor and Delivery
(Description)

### Nursing Mothers
(Description)

### Pediatric Use
(Description)

### Geriatic Use
(Description)

### Gender
(Description)

### Race
(Description)

### Renal Impairment
(Description)

### Hepatic Impairment
(Description)

### Females of Reproductive Potential and Males
(Description)

### Immunocompromised Patients
(Description)

### Others
(Description)

# Administration and Monitoring

### Administration
(Oral/Intravenous/etc)

### Monitoring
(Description regarding monitoring, from Warnings section)
(Description regarding monitoring, from Warnings section)
(Description regarding monitoring, from Warnings section)

# IV Compatibility

## Solution

### Compatible
- Solution 1
- Solution 2
- Solution 3

### Not Tested
- Solution 1
- Solution 2
- Solution 3

### Variable
- Solution 1
- Solution 2
- Solution 3

### Incompatible
- Solution 1
- Solution 2
- Solution 3

## Y-Site

### Compatible
- Solution 1
- Solution 2
- Solution 3

### Not Tested
- Solution 1
- Solution 2
- Solution 3

### Variable
- Solution 1
- Solution 2
- Solution 3

### Incompatible
- Solution 1
- Solution 2
- Solution 3

## Admixture

### Compatible
- Solution 1
- Solution 2
- Solution 3

### Not Tested
- Solution 1
- Solution 2
- Solution 3

### Variable
- Solution 1
- Solution 2
- Solution 3

### Incompatible
- Solution 1
- Solution 2
- Solution 3

## Syringe

### Compatible
- Solution 1
- Solution 2
- Solution 3

### Not Tested
- Solution 1
- Solution 2
- Solution 3

### Variable
- Solution 1
- Solution 2
- Solution 3

### Incompatible
- Solution 1
- Solution 2
- Solution 3

## TPN/TNA

### Compatible
- Solution 1
- Solution 2
- Solution 3

### Not Tested
- Solution 1
- Solution 2
- Solution 3

### Variable
- Solution 1
- Solution 2
- Solution 3

### Incompatible
- Solution 1
- Solution 2
- Solution 3

# Overdosage

## Acute Overdose

### Signs and Symptoms
(Description)

### Management
(Description)

## Chronic Overdose

### Signs and Symptoms
(Description)

### Management
(Description)

# Pharmacology

## Mechanism of Action
(Description)

## Structure
(Description with picture)

## Pharmacodynamics
(Description)

## Pharmacokinetics
(Description)

## Nonclinical Toxicology
(Description)

# Clinical Studies
(Description)
(Description)
(Description)

# How Supplied
(Description)

# Images

## Drug Images

## Package and Label Display Panel

# Patient Information

## Patient Information from FDA
(Patient Counseling Information)

## Patient Information from NLM
(Link to patient information page)

# Precautions with Alcohol
Alcohol-Sandbox Captopril tablet interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

# Look-Alike Drug Names
- (Paired Confused Name 1a)  (Paired Confused Name 1b)
- (Paired Confused Name 2a)  (Paired Confused Name 2b)
- (Paired Confused Name 3a)  (Paired Confused Name 3b)

# Drug Shortage Status
Drug Shortage

# Price